Emil Assentato - Nukkleus President CEO, Treasurer, Secretary, Director
| NUKK Stock | USD 14.08 0.79 5.94% |
CEO
Mr. Emil Assentato is Chairman of the Board, Chief Executive Officer, Chief Accounting Officer of the Company. Mr. Assentato was previously the Chief Executive Officer of Tradition North America, one of the leading interdealer brokers in the world, and a subsidiary of Compagnie Financiere Tradition, a leading global brand in interdealer broking listed on the Swiss Stock Exchange. He continues today as Chairman of Tradition North America. His career spans over 30 years of Wall Street leadership in Institutional Sales, Marketing and Senior Management. Mr. Assentato and his team were the founding shareholders of FXDD in 2002, and pioneered the brand in the early days of the retail forex industry. Having lead a management buyout of the brand from Tradition, and whilst keeping Tradition as a minority equity partner, Mr. Assentato in recent years, refocused the brand strategy on Asian markets. since 2016.
| Age | 74 |
| Tenure | 9 years |
| Address | 575 Fifth Ave, Jersey City, NJ, United States, 10017 |
| Phone | 212-791-4663 |
| Web | https://www.nukk.com |
Emil Assentato Latest Insider Activity
Tracking and analyzing the buying and selling activities of Emil Assentato against Nukkleus stock is an integral part of due diligence when investing in Nukkleus. Emil Assentato insider activity provides valuable insight into whether Nukkleus is net buyers or sellers over its current business cycle. Note, Nukkleus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nukkleus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Emil Assentato over six months ago Disposition of 200000000 shares by Emil Assentato of Nukkleus subject to Rule 16b-3 | ||
Emil Assentato over six months ago Acquisition by Emil Assentato of 157500000 shares of Nukkleus subject to Rule 16b-3 |
Nukkleus Management Efficiency
The company has return on total asset (ROA) of (3.973) % which means that it has lost $3.973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.4205) %, meaning that it created substantial loss on money invested by shareholders. Nukkleus' management efficiency ratios could be used to measure how well Nukkleus manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Nukkleus' Return On Capital Employed is quite stable compared to the past year. Return On Equity is expected to rise to 2.73 this year, although the value of Return On Tangible Assets are projected to rise to (9.64). At this time, Nukkleus' Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 956.9 K this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 1.1 M.Similar Executives
| Found 1 records | CEO Age | ||
| Steve Levely | Ackroo Inc | N/A | |
Management Performance
| Return On Equity | -7.42 | ||||
| Return On Asset | -3.97 |
Nukkleus Leadership Team
Elected by the shareholders, the Nukkleus' board of directors comprises two types of representatives: Nukkleus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nukkleus. The board's role is to monitor Nukkleus' management team and ensure that shareholders' interests are well served. Nukkleus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nukkleus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jamal Khurshid, COO Director | ||
| Emil Assentato, President CEO, Treasurer, Secretary, Director | ||
| Menachem Shalom, CEO Director | ||
| Andrew MBA, Chief Officer | ||
| Shawn Dilkes, Chief Officer |
Nukkleus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nukkleus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.42 | ||||
| Return On Asset | -3.97 | ||||
| Profit Margin | (1.44) % | ||||
| Operating Margin | (4.35) % | ||||
| Current Valuation | 53.01 M | ||||
| Shares Outstanding | 4.79 M | ||||
| Shares Owned By Insiders | 52.36 % | ||||
| Shares Owned By Institutions | 1.12 % | ||||
| Number Of Shares Shorted | 220.23 K | ||||
| Price To Earning | (40.00) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (50.59) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.